Clin2
NCT07255664Possibly a fitRecruiting

TIL therapy for advanced colorectal or prostate cancer

Metastatic Colorectal CancerProstate Cancer MetastaticProstate Cancer Locally Advanced

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests a new type of immunotherapy that uses your own white blood cells (TILs) to fight advanced colorectal or prostate cancer. You will have surgery to remove a tumor, then your TIL cells are grown in a lab and given back to you along with other treatments to boost your immune system.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
12 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have colorectal cancer that has spread to other parts of the body (stage IV) or prostate cancer that is locally advanced (stage III) or has spread (stage IV).
  • You must have tried all standard treatments available to you through your national health system, and they either didn't work, weren't suitable, or you chose not to take them.
  • You must have at least one tumor that can be removed with surgery to make the TIL therapy, and you must be healthy enough to have that surgery.
  • You must be in good enough health to have a life expectancy of at least 6 months, and you must be able to get to a hospital within 50 km of your home.
  • You must have good organ function (bone marrow, liver, kidneys) and be able to take medications that suppress the immune system.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT01174121Recruiting· Phase 2
Immunotherapy made from your tumor-fighting immune cells

This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for certain metastatic cancers. It’s designed for people whose cancer has not responded to standard treatments and who can safely provide a small tumor sample for cell-making.

Bethesda, Maryland
NCT06532799Recruiting· Phase 1/Phase 2
TIL therapy with pembrolizumab for advanced stomach and esophageal cancer

This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.

Beijing, Beijing Municipality
NCT06532812Recruiting· Phase 1/Phase 2
TIL therapy plus immunotherapy for advanced breast cancer

This trial tests a personalized therapy using your own immune cells (TILs) combined with immunotherapy to fight advanced breast cancer that has not responded to other treatments. It may help if you have a tumor that can be biopsied and you are generally healthy enough for the procedures.

Beijing, Beijing Municipality
NCT05087745Recruiting· Early Phase 1
TIL therapy for advanced solid tumors

This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.

Hangzhou, Zhejiang
NCT06530303Recruiting· Phase 1/Phase 2
Personalized immune cell therapy for colorectal cancer

This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.

Beijing, Beijing Municipality
NCT06088472Recruiting· Phase 1
TIL therapy for advanced solid tumors

This trial tests a treatment made from your own immune cells (TILs) that are taken from a tumor, grown in a lab, and then given back to you to fight cancer. It's for people with solid tumors that have spread or come back after treatment.

Xuzhou, Jiangsu

Hear when a new Metastatic Colorectal Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.